Discovery, Synthesis, and Optimization of 1,2,4-Triazolyl Pyridines Targeting Mycobacterium tuberculosis
ACS Infectious Diseases · 10.11.2023 · 9 (11) · 2282-2298
DOI: 10.1021/acsinfecdis.3c00341 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 03.10.2023. Verfasst von Tomayo Berida und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of BioMolecular Sciences, University of Mississippi, University, Mississippi 38677, United States. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
The rise in multidrug resistant tuberculosis cases underscores the urgent need to develop new treatment strategies for tuberculosis. Herein, we report the discovery and synthesis of a new series of compounds containing a 3-thio-1,2,4-triazole moiety that show inhibition of Mycobacterium tuberculosis (Mtb) growth and survival. Structure-activity relationship studies led us to identify several potent analogs displaying low micromolar to nanomolar inhibitory activity, specifically against Mtb. The potent analogs demonstrated no cytotoxicity in mammalian cells at over 100 times the effective concentration required in Mtb and were bactericidal against Mtb during infection of macrophages. In the exploratory ADME investigations, we observed suboptimal ADME characteristics, which prompted us to identify potential metabolic liabilities for further optimization. Our preliminary investigations into the mechanism of action suggest that this series is not engaging the promiscuous targets that arise from many phenotypic screens. We selected for resistant mutants with the nanomolar potent nitro-containing compound 20 and identified resistant isolates with mutations in genes required for coenzyme F420 biosynthesis and the nitroreductase Ddn. This suggests that the aromatic nitro-1,2,4-triazolyl pyridines are activated by F420-dependent Ddn activity, similar to the nitro-containing TB drug pretomanid. We were able to circumvent the requirement for F420-dependent Ddn activity using compounds that contained non-nitro groups, identifying a key feature to be modified to avoid this predominant resistance mechanism. These studies provide the foundation for the development of a new class of 1,2,4-triazole compounds for the treatment of tuberculosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of BioMolecular Sciences, University of Mississippi, University, Mississippi 38677, United States.
- Department of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
- Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, 1682 Campus Delivery, Fort Collins, Colorado 80523, United States.
- National Center for Natural Products Research, University of Mississippi, University, Mississippi 38677, United States.
- Department of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbrücken 66123, Germany.
ORCID-Profile: Tomayo Berida, Shamba Chatterjee, Destinee L Manning, Pankaj Pandey, Robert J Doerksen, Mary Jackson, Christian Ducho, Sudeshna Roy
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- National Cancer Institute
- National Center for Research Resources
- Agricultural Research Service
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Berida, T., McKee, S. R., Chatterjee, S., Manning, D. L., Li, W., Pandey, P., Tripathi, S. K., Mreyoud, Y., Smirnov, A., Doerksen, R. J., Jackson, M., Ducho, C., Stallings, C. L., & Roy, S. (2023). Discovery, Synthesis, and Optimization of 1,2,4-Triazolyl Pyridines Targeting Mycobacterium tuberculosis. ACS Infectious Diseases, 9(11), 2282-2298. https://doi.org/10.1021/acsinfecdis.3c00341
Vancouver
Berida T, McKee SR, Chatterjee S, Manning DL, Li W, Pandey P, et al. Discovery, Synthesis, and Optimization of 1,2,4-Triazolyl Pyridines Targeting Mycobacterium tuberculosis. ACS Infectious Diseases. 2023;9(11):2282-2298. doi:10.1021/acsinfecdis.3c00341
BibTeX
@article{Berida2023,
author = {Berida, Tomayo and McKee, Samuel R and Chatterjee, Shamba and Manning, Destinee L and Li, Wei and Pandey, Pankaj and Tripathi, Siddharth Kaushal and Mreyoud, Yassin and Smirnov, Asya and Doerksen, Robert J and Jackson, Mary and Ducho, Christian and Stallings, Christina L and Roy, Sudeshna},
title = {Discovery, Synthesis, and Optimization of 1,2,4-Triazolyl Pyridines Targeting Mycobacterium tuberculosis},
journal = {ACS Infectious Diseases},
year = {2023},
volume = {9},
number = {11},
pages = {2282--2298},
doi = {10.1021/acsinfecdis.3c00341}
}
EUVIMED